Androgen deprivation therapy (ADT), aimed at suppressing the aberrant activation of androgen receptor (AR) signaling, remains the standard of care for advanced prostate cancer [6,7,8]; instead, the treatment for metastatic castration-resistant prostate cancer (mCRPC) patients is based on chemo-radiotherapy regimens. This evidence concerns the gene AR and prostate cancer.